首页> 外文期刊>Journal of immunology research. >Th17-Associated Cytokines as a Therapeutic Target for Steroid-Insensitive Asthma
【24h】

Th17-Associated Cytokines as a Therapeutic Target for Steroid-Insensitive Asthma

机译:Th17相关的细胞因子作为类固醇不敏感哮喘的治疗靶标

获取原文
           

摘要

Steroid-insensitive asthma is an infrequent but problematic airway disease that presents with persistent symptoms, airflow limitation, or recurrent exacerbations even when treated with steroid-based therapies. Because of unsatisfactory results obtained from currently available therapies for steroid-insensitive asthma, a better understanding of its pathogenesis and the development of new targeted molecular therapies are warranted. Recent studies indicated that levels of interleukin (IL)-17 are increased and both eosinophils and neutrophils infiltrate the airways of severe asthmatics. IL-17 is a proinflammatory cytokine mainly secreted from helper T (Th) 17 cells and is important for the induction of neutrophil recruitment and migration at sites of inflammation. This review focuses on the pathogenetic role of Th17 cells and their associated cytokines in steroid-insensitive asthma and discusses the prospects of novel therapeutic options targeting the Th17 signaling pathway.
机译:类固醇不敏感的哮喘是一种罕见的但有问题的气道疾病,即使使用基于类固醇的疗法治疗,也表现出持续的症状,气流受限或反复发作​​。由于从目前可获得的对类固醇不敏感的哮喘的治疗中不能获得令人满意的结果,因此有必要更好地了解其发病机理并开发新的靶向分子疗法。最近的研究表明,白细胞介素(IL)-17的水平升高,嗜酸性粒细胞和嗜中性粒细胞均渗入严重哮喘患者的气道。 IL-17是一种主要从辅助性T(Th)17细胞分泌的促炎细胞因子,对于诱导中性粒细胞募集和在炎症部位的迁移很重要。这篇综述集中于在类固醇不敏感哮喘中Th17细胞及其相关的细胞因子的致病作用,并讨论了针对Th17信号通路的新型治疗选择的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号